Literature DB >> 22870493

Treatment of rheumatoid arthritis in patients with concomitant chronic hepatitis C infection.

Amy M Joseph.   

Abstract

Hepatitis C virus (HCV) infection is present in 1.8% of the general US population and its prevalence worldwide is estimated at 2-3%. HCV infected patients with concomitant rheumatoid arthritis (RA) pose a particular challenge to the rheumatologist because of the risks of treatment with disease-modifying medications in patients with chronic liver infection. In this paper the difficulties of diagnosing RA in HCV patients and the safety of RA treatment in patients with both conditions are discussed.

Entities:  

Keywords:  biological-response modifiers; disease-modifying antirheumatic drugs; hepatitis C; rheumatoid arthritis

Year:  2012        PMID： 22870493      PMCID： PMC3383526          DOI： 10.1177/1759720X11424459

Source DB:  PubMed          Journal:  Ther Adv Musculoskelet Dis        ISSN： 1759-720X            Impact factor:   5.346


  44 in total

1.  Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS)

Authors:  E L Murphy; S M Bryzman; S A Glynn; D I Ameti; R A Thomson; A E Williams; C C Nass; H E Ownby; G B Schreiber; F Kong; K R Neal; G J Nemo
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

2.  Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia.

Authors:  Mark H Wener; Kathleen Hutchinson; Chihiro Morishima; David R Gretch
Journal:  Arthritis Rheum       Date:  2004-07

3.  Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection.

Authors:  Frank A Parke; John D Reveille
Journal:  Arthritis Rheum       Date:  2004-10-15

4.  Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C.

Authors:  Owonayo Oniankitan; Christophe Duvoux; Dominique Challine; Arianne Mallat; Xavier Chevalier; Jean-Michel Pawlotsky; Pascal Claudepierre
Journal:  J Rheumatol       Date:  2004-01       Impact factor: 4.666

5.  Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial.

Authors:  Kazuaki Inoue; Kazuhiko Sekiyama; Masaya Yamada; Tsunamasa Watanabe; Hiroshi Yasuda; Makoto Yoshiba
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

6.  Anti-cyclic citrullinated peptide antibodies in hepatitis C virus associated rheumatological manifestations and Sjogren's syndrome.

Authors:  D Sène; P Ghillani-Dalbin; N Limal; V Thibault; T van Boekel; J-C Piette; P Cacoub
Journal:  Ann Rheum Dis       Date:  2006-03       Impact factor: 19.103

7.  High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C.

Authors:  B D Clifford; D Donahue; L Smith; E Cable; B Luttig; M Manns; H L Bonkovsky
Journal:  Hepatology       Date:  1995-03       Impact factor: 17.425

8.  The positivity of rheumatoid factor and anti-cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection.

Authors:  E Orge; A Cefle; Ayten Yazici; N Gürel-Polat; S Hulagu
Journal:  Rheumatol Int       Date:  2009-06-23       Impact factor: 2.631

9.  Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection.

Authors:  J R Peterson; F C Hsu; P A Simkin; M H Wener
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

10.  Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis.

Authors:  Raimon Sanmartí; Eduard Graell; Maria L Perez; Guadalupe Ercilla; Odette Viñas; Jose A Gómez-Puerta; Jordi Gratacós; Alejandro Balsa; Maria J Gómara; Marta Larrosa; Juan D Cañete; Isabel Haro
Journal:  Arthritis Res Ther       Date:  2009-09-02       Impact factor: 5.156
View more
  2 in total

Review 1.  Clinical connection between rheumatoid arthritis and liver damage.

Authors:  Biljana Radovanović-Dinić; Snežana Tešić-Rajković; Valentina Zivkovic; Saša Grgov
Journal:  Rheumatol Int       Date:  2018-04-07       Impact factor: 2.631

2.  Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics.

Authors:  Sheryl Trueman; Mohamed-Eslam F Mohamed; Tian Feng; Ana Paula Lacerda; Thomas Marbury; Ahmed A Othman
Journal:  J Clin Pharmacol       Date:  2019-04-11       Impact factor: 3.126
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.